MIRA - MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Story updates
12:34:23 PM UTC
SquawkNews
MIRA advanced its Ketamir-2 Phase 2a CIPN trial protocol to IRB review after FDA feedback and is targeting site initiation in Q1 2027.Key Highlights:Original SEC Filing: MIRA PHARMACEUTICALS, INC. [ MIRA ] - 8-K - Sep. 17, 2026This is an AI-powered summary. It may contain inaccuracies. Consider ver…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.